Revised forecast
Fiscal year ending December 2026 · Cumulative second quarter and full yearPrevious forecast published 15 May 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
In the A-COMS business, implementation at newly opened clinics and the acquisition of migration contracts from other companies' systems progressed, expanding subscription-based recurring revenue. Sales of original equipment also remained firm, and the profitability of the core business exceeded plan. In addition, the transfer of all shares of the consolidated subsidiary ペリカン resulted in the elimination of losses following its removal from the scope of consolidation.
Loss on sale of shares in an affiliated company: ¥130 million (one-off extraordinary loss)
| Item | Details |
|---|---|
| Net Sales | Second quarter (cumulative) 1,400 / Full year 2,400 → Second quarter (cumulative) 1,619 / Full year 2,700（Second quarter (cumulative) 15.7 / Full year 12.5） |
| Operating profit | Second quarter (cumulative) 50 / Full year 120 → Second quarter (cumulative) 81 / Full year 160（Second quarter (cumulative) 63.2 / Full year 33.3） |
| Ordinary income | Second quarter (cumulative) 58 / Full year 130 → Second quarter (cumulative) 91 / Full year 165（Second quarter (cumulative) 57.5 / Full year 26.9） |
| Profit attributable to owners of the parent | Second quarter (cumulative) -80 / Full year -25 → Second quarter (cumulative) -45 / Full year 15 |
| Net income per share | Second quarter (cumulative) -7.79 / Full year -2.44 → Second quarter (cumulative) -4.48 / Full year 1.46 |
| Fiscal Period Covered | Fiscal year ending December 2026 |
| Period Covered | Cumulative second quarter and full year |
| Publication date of previous forecast | 15 May 2026 |
| Previous-period results | Cumulative second quarter of the fiscal year ended December 2025 Net sales: ¥1,883 million; operating profit: ¥25 million; ordinary profit: ¥30 million; net income attributable to owners of the parent for the quarter: ¥115 million; net income per share for the quarter: ¥11.26 / Fiscal year ended December 2025 Net sales: ¥3,927 million; operating profit: ¥140 million; ordinary profit: ¥148 million; net income attributable to owners of the parent: ¥258 million; net income per share: ¥25.16 |
| Reason for the revision | In the A-COMS business, implementation at newly opened clinics and the acquisition of migration contracts from other companies' systems progressed, expanding subscription-based recurring revenue. Sales of original equipment also remained firm, and the profitability of the core business exceeded plan. In addition, the transfer of all shares of the consolidated subsidiary ペリカン resulted in the elimination of losses following its removal from the scope of consolidation. |
| Details and amount of extraordinary loss | Loss on sale of shares in an affiliated company: ¥130 million (one-off extraordinary loss) |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The profitability of the core business exceeded plan because implementation at newly opened clinics and migration contracts from other companies' systems progressed in the A-COMS business, expanding subscription-based recurring revenue, while sales of original equipment remained firm. In addition, all shares of the consolidated subsidiary ペリカン were transferred on 31 March 2026, resulting in the elimination of losses following its removal from the scope of consolidation. Even assuming the recognition of a ¥130 million loss on the sale of shares in an affiliated company as a one-off extraordinary loss, full-year net income is expected to turn profitable.